Drug intelligence / Profile preview

KR24258

Development stage: Preclinical
Lead developer: Jiangxi Kvvit Pharmaceutical

Overview

KR24258 is a preclinical drug candidate currently under development by Jiangxi Kvvit Pharmaceutical (also known as Qingfeng Pharmaceutical Group). As of the latest pipeline updates, the drug is in the preclinical (PCC) stage. Publicly available information regarding its specific biological target, therapeutic modality, and primary disease indication remains limited, although it is categorized within the company's broader research efforts which include oncology, infectious diseases, and central nervous system (CNS) disorders.

Beyond the preview

Go deeper on KR24258.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KR24258.

Explore the full profile